BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced it will release its Q1 2025 financial results on Wednesday, May 14, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET to discuss the financial results and provide a business update. Investors can join via domestic (1-888-506-0062) or international (1-973-528-0011) lines using access code 924151. The call will be broadcast live and archived on the company's website in the Investors section.
BioRestorative Therapies (NASDAQ:BRTX), un'azienda in fase clinica specializzata in medicina rigenerativa basata su terapie con cellule staminali, ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 il mercoledì 14 maggio 2025, dopo la chiusura del mercato.
L'azienda terrà una conference call alle 16:30 ET per discutere i risultati finanziari e fornire un aggiornamento aziendale. Gli investitori potranno partecipare tramite linee nazionali (1-888-506-0062) o internazionali (1-973-528-0011) utilizzando il codice di accesso 924151. La chiamata sarà trasmessa in diretta e archiviata nella sezione Investitori del sito web dell'azienda.
BioRestorative Therapies (NASDAQ:BRTX), una empresa en etapa clínica especializada en medicina regenerativa con terapias basadas en células madre, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el miércoles 14 de mayo de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia a las 4:30 p.m. ET para discutir los resultados financieros y proporcionar una actualización del negocio. Los inversores pueden unirse a través de líneas nacionales (1-888-506-0062) o internacionales (1-973-528-0011) usando el código de acceso 924151. La llamada será transmitida en vivo y archivada en la sección de Inversores del sitio web de la empresa.
BioRestorative Therapies (NASDAQ:BRTX)는 줄기세포 기반 치료를 전문으로 하는 임상 단계 재생 의학 회사로, 2025년 1분기 재무 결과를 2025년 5월 14일 수요일 장 마감 후에 발표할 예정입니다.
회사는 동부시간 오후 4시 30분에 재무 결과를 논의하고 사업 업데이트를 제공하는 컨퍼런스 콜을 진행합니다. 투자자들은 국내 전화(1-888-506-0062) 또는 국제 전화(1-973-528-0011)를 통해 접속 코드 924151을 사용하여 참여할 수 있습니다. 이 통화는 회사 웹사이트 투자자 섹션에서 실시간 방송 및 아카이브됩니다.
BioRestorative Therapies (NASDAQ:BRTX), une société en phase clinique spécialisée dans la médecine régénérative à base de thérapies cellulaires souches, a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le mercredi 14 mai 2025, après la clôture du marché.
La société tiendra une conférence téléphonique à 16h30 ET pour discuter des résultats financiers et fournir une mise à jour commerciale. Les investisseurs peuvent participer via des lignes nationales (1-888-506-0062) ou internationales (1-973-528-0011) en utilisant le code d'accès 924151. L'appel sera diffusé en direct et archivé dans la section Investisseurs du site web de la société.
BioRestorative Therapies (NASDAQ:BRTX), ein Unternehmen in der klinischen Phase, das sich auf regenerative Medizin mit stammzellbasierten Therapien spezialisiert hat, hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am Mittwoch, den 14. Mai 2025, nach Börsenschluss zu veröffentlichen.
Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können über nationale (1-888-506-0062) oder internationale (1-973-528-0011) Leitungen mit dem Zugangscode 924151 teilnehmen. Der Anruf wird live übertragen und im Investor-Bereich der Unternehmenswebsite archiviert.
- None.
- None.
MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its first quarter 2025 financial results after market close on Wednesday, May 14, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.
First Quarter 2025 Results Conference Call Details:
| Date: | Wednesday, May 14, 2025 |
| Time: | 4:30 p.m. ET |
| Domestic: | 1-888-506-0062 |
| International: | 1-973-528-0011 |
| Access Code: | 924151 |
The call will also be broadcast live and archived on the Company's website under News & Events/IR Calendar in the Investors section.
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained FDA IND clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering U.S. Food and Drug Administration (FDA) approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ
When will BRTX release its Q1 2025 earnings report?
What time is BioRestorative Therapies Q1 2025 earnings call?
How can I listen to BRTX's Q1 2025 earnings call?
What is BioRestorative Therapies' main business focus?
